These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 15641060)

  • 21. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus.
    Haddouk S; Marzouk S; Jallouli M; Fourati H; Frigui M; Hmida YB; Koubaa F; Sellami W; Baklouti S; Hachicha J; Bahloul Z; Masmoudi H
    Rheumatology (Oxford); 2009 Aug; 48(8):953-7. PubMed ID: 19502474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus.
    Shergy WJ; Kredich DW; Pisetsky DS
    J Rheumatol; 1988 Sep; 15(9):1389-94. PubMed ID: 3264338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
    Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
    Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus.
    Su J; Frostegård AG; Hua X; Gustafsson T; Jogestrand T; Hafström I; Frostegård J
    J Rheumatol; 2013 Nov; 40(11):1856-64. PubMed ID: 24037548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis.
    Kobayashi K; Lopez LR; Shoenfeld Y; Matsuura E
    Ann N Y Acad Sci; 2005 Jun; 1051():442-54. PubMed ID: 16126986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus.
    Reichlin M; Fesmire J; Quintero-Del-Rio AI; Wolfson-Reichlin M
    Arthritis Rheum; 2002 Nov; 46(11):2957-63. PubMed ID: 12428237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?
    Narshi CB; Giles IP; Rahman A
    Lupus; 2011 Jan; 20(1):5-13. PubMed ID: 21138982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon.
    Rodriguez VE; Gonzalez-Pares EN; Rivera C
    P R Health Sci J; 2006 Dec; 25(4):307-13. PubMed ID: 17550096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
    Vuilleumier N; Charbonney E; Fontao L; Alvarez M; Turck N; Sanchez JC; Burkhard PR; Mensi N; Righini M; Reber G; James R; Mach F; Chevrolet JC; Dayer JM; Frostegard J; Roux-Lombard P
    Clin Sci (Lond); 2008 Jul; 115(1):25-33. PubMed ID: 18088236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus.
    Tso TK; Huang WN; Huang HY; Chang CK
    Rheumatology (Oxford); 2006 Sep; 45(9):1148-53. PubMed ID: 16527878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus.
    Nowak B; Szmyrka-Kaczmarek M; Durazińska A; Płaksej R; Borysewicz K; Korman L; Wiland P
    Adv Clin Exp Med; 2012; 21(3):331-5. PubMed ID: 23214196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies.
    Gómez-Zumaquero JM; Tinahones FJ; De Ramón E; Camps M; Garrido L; Soriguer FJ
    Rheumatology (Oxford); 2004 Apr; 43(4):510-3. PubMed ID: 14872100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus.
    Abe H; Tsuboi N; Suzuki S; Sakuraba H; Takanashi H; Tahara K; Tonozuka N; Hayashi T; Umeda M
    J Rheumatol; 2001 May; 28(5):990-5. PubMed ID: 11361227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of three systemic lupus erythematosus susceptibility factors, PD-1.3A, C4AQ0, and low levels of mannan-binding lectin, with autoimmune manifestations in Icelandic multicase systemic lupus erythematosus families.
    Kristjansdottir H; Saevarsdottir S; Gröndal G; Alarcón-Riquelme ME; Erlendsson K; Valdimarsson H; Steinsson K
    Arthritis Rheum; 2008 Dec; 58(12):3865-72. PubMed ID: 19035512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of anticardiolipin autoantibodies in the pathogenesis of autoimmune hemolytic anemia in systemic lupus erythematosus.
    Sthoeger Z; Sthoeger D; Green L; Geltner D
    J Rheumatol; 1993 Dec; 20(12):2058-61. PubMed ID: 8014933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical significance of anti-cardiolipin antibody in patients with systemic lupus erythematosus (SLE)].
    Aoki K; Takeuchi T; Itoh I; Takano Y; Itoh T; Hosono O; Koide J; Abe T
    Ryumachi; 1994 Dec; 34(6):961-6. PubMed ID: 7863386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated expression of the Brn-3a and Brn-3b transcription factors in systemic lupus erythematosus correlates with antibodies to Brn-3 and overexpression of Hsp90.
    Ripley BJ; Rahman MA; Isenberg DA; Latchman DS
    Arthritis Rheum; 2005 Apr; 52(4):1171-9. PubMed ID: 15818685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.